Company: Kite Pharma
Job title: Senior Director, Process Development
Andy Snowden leads the Allogeneic Process Design function at Kite Pharma. His team is responsible for process development of cell therapies including ‘off-the-shelf’ allogeneic cell therapy products, together with the development of related technologies.
Over the course of his career in biopharmaceutical development, Andy has focused on preclinical, early and late phase bioprocess development, tech transfer, technology development and CMC strategy. Prior to joining Kite Pharma in 2018 he led the upstream biologics development function at Gilead Sciences, focusing on production cell line engineering and the development of scalable and robust bioreactor production process. Over course of his career has held leadership roles of increasing scope and responsibility at Macrogenics, Amgen, Biogen, Genentech and Sangamo Biosciences. Dr. Snowden received his Ph.D. in Biochemistry from the University of Dundee, Scotland, UK.